Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 140
- Registration Number
- NCT06156514
- Locations
- 🇲🇽
National Cancer Institute of Mexico, México, Ciudad De México, Mexico
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 270
- Registration Number
- NCT06151574
- Locations
- 🇵🇹
Hospital CUF Porto, Porto, Portugal
🇺🇸Scripps Cancer Center Torrey Pines, La Jolla, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT06145412
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 54
- Registration Number
- NCT06140966
- Locations
- 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06140407
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT06132113
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇺🇸University of Miami, Miami, Florida, United States
🇧🇪Edegem - UNIV UZ Antwerpen, Edegem, Belgium
BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Bio-Thera Solutions
- Target Recruit Count
- 526
- Registration Number
- NCT06123884
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1016
- Registration Number
- NCT06119581
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇦🇹Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 100
- Registration Number
- NCT06115499
- Locations
- 🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Saint Francis Medical Center, Cape Girardeau, Missouri, United States
🇺🇸Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Xuekui Liu
- Target Recruit Count
- 52
- Registration Number
- NCT06107114
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.